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Abstract We recently provided evidence that an intrinsic reward-related signal—triggered by
successful learning in absence of any external feedback—modulated the entrance of new
information into long-term memory via the activation of the dopaminergic midbrain, hippocampus,
and ventral striatum (the SN/VTA-Hippocampal loop; Ripollés et al., 2016). Here, we used a double-
blind, within-subject randomized pharmacological intervention to test whether this learning process
is indeed dopamine-dependent. A group of healthy individuals completed three behavioral sessions
of a language-learning task after the intake of different pharmacological treatments: a
dopaminergic precursor, a dopamine receptor antagonist or a placebo. Results show that the
pharmacological intervention modulated behavioral measures of both learning and pleasantness,
inducing memory benefits after 24 hr only for those participants with a high sensitivity to reward.
These results provide causal evidence for a dopamine-dependent mechanism instrumental in
intrinsically regulated learning and further suggest that subject-specific reward sensitivity
drastically alters learning success.
DOI: https://doi.org/10.7554/eLife.38113.001
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Introduction
Growing evidence both from animal and human studies support the notion that midbrain dopami-
nergic neurons of the substantia nigra/ventral tegmental area complex (SN/VTA), along with the ven-
tral striatum (VS) and the hippocampus (HP), form a functional loop (the SN/VTA-HP loop) in the
service of learning and memory (Lisman and Grace, 2005; Goto and Grace, 2005; Lisman et al.,
2011; Shohamy and Adcock, 2010; Kamiński et al., 2018). In the downward arm of the circuit, sig-
nals are sent from the HP to the SN/VTA through the VS, which is thought to integrate affective,
motivational, and goal-directed information into the loop (Lisman and Grace, 2005; Goto and
Grace, 2005). In the upward arm of the loop, dopamine is released from the SN/VTA back into the
HP, which in turn enhances memory formation and learning through long-term potentiation (LTP)
processes (Lisman et al., 2011; Lisman and Grace, 2005; Shohamy and Adcock, 2010). Within this
loop, dopamine plays a critical role, as its release promotes the creation of stable memories by
allowing LTP to persist over time (Bethus et al., 2010; Frey et al., 1990; Hansen and Manahan-
Vaughan, 2014; Huang and Kandel, 1995; McNamara et al., 2014; Rossato et al., 2009).
In this vein, fMRI research in humans has consistently shown that both explicit (Adcock et al.,
2006; Wittmann et al., 2005; Wolosin et al., 2012; Callan and Schweighofer, 2008) and implicit
reward (Ripollés et al., 2016), and even intrinsic motivational states (i.e., curiosity; Gruber et al.,
2014), can promote the storage of new information into long-term memory through the activation
of the SN/VTA-HP loop (see Figure 8 in, Ripollés et al., 2016). However, although fMRI activity
within the SN/VTA is usually associated with the release of dopamine (Düzel et al., 2009 ;
Ferenczi et al., 2016; Knutson and Gibbs, 2007; Salimpoor et al., 2011; Schott et al., 2008), neu-
roimaging studies can only provide indirect evidence of the actual involvement of the dopaminergic
mesolimbic system. In order to prove that a dopamine-dependent mechanism plays a critical role in
learning and memory processes, one avenue to pursue is to directly manipulate dopaminergic neu-
rotransmission in the human brain through pharmacological interventions. In this vein, several studies
have shown that administration of dexamphetamine and methylphenidate (which increase dopamine
concentrations in the synapsis by blocking its reuptake; Breitenstein et al., 2004; Whiting et al.,
2007; Whiting et al., 2008; Linssen et al., 2014) and specially, levodopa (the immediate precursor
of dopamine) can enhance memory and learning in both healthy (Shellshear et al., 2015;
Bunzeck et al., 2014; Chowdhury et al., 2012; Knecht et al., 2004) and clinical populations
(Berthier et al., 2011).
We recently provided behavioral, functional and physiological evidence by means of fMRI and
skin conductance response, showing that an intrinsic reward-related signal—triggered by successful
learning in absence of any external feedback or explicit reward—modulated the entrance of new
information into long-term memory via the activation of the SN/VTA-HP loop (Ripollés et al., 2016).
Here, we used a double-blind, within-subject randomized pharmacological intervention to directly
assess the hypothesis that synaptic dopamine availability plays a causal role in this learning process.
A group of 29 individuals were asked to perform a language-learning task (that mimics our capacity
to learn the meaning of new-words presented in verbal contexts; Ripollés et al., 2014;
Ripollés et al., 2016; Ripollés et al., 2017; Mestres-MisseMissé et al., 2007) after the intake of
three different pharmacological treatments: a dopaminergic precursor (levodopa, 100
mg +carbidopa, 25 mg), a dopamine antagonist (risperidone, 2 mg), or a placebo (lactose). Levo-
dopa is rapidly taken up by dopaminergic neurons, transformed into dopamine and stored in
vesicles from which it will be released into the synaptic cleft each time the neuron fires. Thus, levo-
dopa leads to a general increase in dopamine available for release in brain areas innervated by
dopaminergic afferents. On the other hand, risperidone—a dopamine antagonist—interferes with
dopaminergic neurotransmission by binding with a group of receptors known as D2 or D2-like
(Burstein et al., 2005). Therefore, in the presence of risperidone, the transmission of dopamine-
mediated signals to post-synaptic neurons will be reduced due to the blockade of the D2 receptor
family.
We aimed at assessing the influence of dopamine signaling on learning and reward using the
pharmacological approach described above. Each of the two experimental sessions involving active
drugs were intended to shift dopaminergic neurotransmission away from each individual’s
Ripollés et al. eLife 2018;7:e38113. DOI: https://doi.org/10.7554/eLife.38113 2 of 23
Research advance Neuroscience
physiological status, as measured in a placebo session, and in opposite directions: levodopa to
enhance the dopamine availability for release into the synapse, and risperidone to reduce synaptic
transmission of the dopamine-associated signal by hindering dopamine-receptor interactions (for the
use of levodopa or risperidone during cognitive tasks, see e.g. Rabella et al., 2016; Wittmann and
D’Esposito, 2015; de Vries et al., 2010; Knecht et al., 2004) . Accordingly, we predicted that
behavioral measures of both learning and reward should increase and decrease under levodopa and
risperidone, thus modulating—with opposite effects—the memory benefits for the learned words
after a consolidation period (24 hr).
Results
Twenty-nine healthy participants completed a behavioral version of our word-learning task (see
Materials and methods), in which the meaning of a new-word could be learned from the context pro-
vided by two sentences built with an increasing degree of contextual constraint (Mestres-
Missé et al., 2010). Only half of the pairs of sentences disambiguated multiple meanings, allowing
the encoding of a congruent meaning of the new-word during its second presentation (M+ condi-
ition). For the other pairs, the new-word was not associated with a congruent meaning across the
sentences and could not be learned (M- condition). This condition, as in our previous study
(Ripollés et al., 2016), was included to control for possible confounds related to novelty, attention
and task difficulty (Guitart-Masip et al., 2010; Bunzeck and Düzel, 2006; Boehler et al., 2011). At
the end of each learning trial (i.e. after the second sentence for a particular new-word appeared),
participants first provided a confidence rating (a subjective evaluation of their performance) and
then rated their emotions with respect to arousal and pleasantness. After approximately 24 hr (no
drug intake occurred during the second day of testing), participants completed a recognition test to
assess their learning (chance level was 25%; see Materials and methods). Three participants were
excluded from the analyses (see Materials and methods) and thus the final sample was reduced to
26 individuals (17 women, mean age = 22.27 ± 3.69).
We first assessed whether our participants’ performance under the placebo condition replicated
our previous results. Participants ascribed correct meaning to 60 ± 10% of new-words from the M+
condition during the encoding phase. In 61 ± 15% of the M- trials, participants correctly indicated an
absence of coherent meaning. After 24 hr, participants still recognized the correct meaning of 65 ±
17% of learned new-words during the encoding phase [significantly above 25% chance level, t(25)
=12.28, p<0.001, d = 2.33; Bayes Factor-BF10- equal to 1.9e + 9] and correctly indicated that 41 ±
22% of M- new-words identified during the encoding phase had no meaning ascribed [significantly
above 25% chance level, t(25)=3.70, p<0.001, d = 0.70; BF10 = 35.38].
In order to compare this performance with our previous results (24 participants from Exp. three in
Ripollés et al., 2016), we submitted the learning scores to a mixed repeated measures ANOVA with
Condition (M+,M-) as a within-subjects variable and Group (Pharmacological Group, Exp. 3 in
Ripollés et al., 2016) as a between subjects variable. No significant effect of Group [Learning Day 1:
F(1,48)=0.246, p=0.622, partial h2 = 0.005, BFInclusion = 0.297; Recognition Day 2: F(1,48)=3.56,
p=0.065, partial h2 = 0.069, BFInclusion = 1.05] or Group  Condition interaction [Learning Day 1: F
(1,48)=0.749, p=0.391, partial h2 = 0.015, BFInclusion = 0.381; Recognition Day 2: F(1,48)=0.222,
p=0.639, partial h2 = 0.005, BFInclusion = 0.313] was found for the learning scores of Day 1 or the rec-
ognition rate after 24 hr. This shows that the new group of participants, during the placebo session,
learned and remembered words from the M+ condition and correctly identified M- words (i.e. no
meaning ascribed) at the same rate as in our previous experiment.
We then focused our analyses on learned (on Day 1) and still remembered (on Day 2) M+ new
words. In our previous work (Ripollés et al., 2016), this was the condition associated to the largest
fMRI activity within the SN/VTA-HP loop, the largest physiological response and the highest subjec-
tive pleasantness ratings, even when compared with learned words that were forgotten after 24 hr
(as a control, we used M- new-words correctly identified during the encoding phase and after 24 hr).
Accordingly, in the present study subjective pleasantness and confidence ratings on Day 1 were
higher for remembered than for forgotten M+ new words in the 24 hr recognition test [pleasantness,
t(25)=2.75, p=0.011, d = 0.42, BF10 = 4.39; confidence, t(25)=4.56, p<0.001, d = 0.68,
BF10 = 232.82], while no difference in arousal ratings was encountered [t(25)=0.20, p=0.835,
d = 0.025, BF10 = 0.21]. In replicating our previous results (Ripollés et al., 2016), these findings
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confirm that intrinsic reward (i.e. derived from an internal monitoring of learning success) had a mod-
ulatory effect on long-term memory. Regarding the M- control condition, as expected, there was no
difference in subjective pleasantness [t(25)=1.40, p=0.172, d = 0.26, BF10 = 0.49], arousal [t(25)
=1.28, p=0.212, d = 0.20, BF10 = 0.43] or confidence ratings [t(25)=1.18, p=0.247, d = 0.18,
BF10 = 0.38] for M- new-words which were correctly identified during the encoding phase and still
correctly rejected in the 24 hr test and those which were not. When submitting these ratings to a
mixed repeated measures ANOVA with Condition (M+,M-) and Group (Pharmacological, Previous
Data) as factors (in our previous analyses we excluded four participants from the rating analyses, see
Ripollés et al., 2016; thus in this ANOVA we compare 20 participants from the previous dataset
against 26 for the placebo session), no significant effect of Group [Pleasantness: F(1,44)=0.143,
p=0.707, partial h2 = 0.003, BFInclusion = 0.349; Arousal: F(1,44)=1.66, p=0.204, partial h2 = 0.036,
BFInclusion = 0.80; Confidence: F(1,44)=3.49, p=0.068, partial h2 = 0.073, BFInclusion = 1.17] or
Group  Condition interaction [Pleasantness: F(1,44)=0.239, p=0.627, partial h2 = 0.005, BFInclu-
sion = 0.321; Arousal: F(1,44)=0.216, p=0.645, partial h2 = 0.005, BFInclusion = 0.304; Confidence: F
(1,44)=0.028, p=0.868, partial h2 = 0.001, BFInclusion = 0.280] was found. This shows that participants’
ratings were also in line with those of our previous experiment (Ripollés et al., 2016).
Hence, we calculated the drug effect on the behavioral data. Specifically, for the levodopa and
risperidone interventions and for each subject, we calculated the percentages of change in learning
scores and behavioral ratings with respect to the placebo session (see Materials and methods). Nota-
bly, for the M+ condition, our findings show a pharmacological modulation of learning performance
and behavioral reward ratings. The percentage of learned words during the encoding phase was
higher under levodopa than under risperidone [as compared to placebo; t(25)=2.72, p=0.012,
d = 0.56, BF+0=8.26]. Importantly, this effect was still present at 24 hr for the total number of
remembered new-words [t(25)=2.10, p=0.046, d = 0.45, BF+0=2.62; see Figure 1A]. In addition,
while no significant changes were found for the arousal ratings [t(25)=0.31, p=0.757, d = 0.049,
BF+0=0.26], the drug effect approached significance for confidence ratings [t(25)=2.05, p=0.051,
d = 0.51, BF+0=2.40] and was significant for pleasantness ratings [t(25)=2.70, p=0.012, d = 0.64,
BF+0=7.93], where scores for remembered words at 24 hr where higher under levodopa than under
risperidone (as compared to placebo; see Figure 1B). There was not, however, a significant effect of
drug on the recognition rate [i.e. the percentage of remembered words in the recognition test of
Day 2 compared to those that were learned on Day 1; t(25)=-0.013, p=0.989, d = 0.003, BF+0=0.20].
This suggests that the pharmacological intervention was able to modulate measures of reward,
memory and online learning selectively during the main M+ condition (see the Individual Variability
of the Drug Effect section of Appendix I, for a more in depth description of the individual differences
found for the drug effect for each measure). Additional analyses using the values for the three ses-
sions separately (instead of the percentage of change from placebo) further confirmed this pattern
of results (see the Supplemental Behavioral Analyses section of Appendix 1 and Figure 1—figure
supplementary 1A–C).
As expected, for the control M- condition no significant differences between the risperidone and
levodopa interventions as compared to placebo were found for the online learning scores on Day 1
[t(25)=1.53, p=0.137, d = 0.28, BF+0=1.08], the total number of correctly rejected M- words at 24 hr
[t(25)=0.62, p=0.538, d = 0.15, BF+0=0.35], the recognition rate [percentage of words correctly
rejected on Day 2, in respect to those correctly rejected on Day1; t(25)=-0.04, p=0.968, d = 0.011,
BF+0=0.20; see Figure 1A], or the subjective ratings of arousal [t(23)=1.72, p=0.097, d = 0.45,
BF+0=1.46] and confidence [t(23)=0.36, p=0.720, d = 0.10, BF+0=0.28; see Figure 1B; two partici-
pants were excluded from the rating analyses after not correctly rejecting any M- word at 24 hr from
those correctly rejected during encoding in the levodopa intervention]. For the pleasantness ratings,
however, the difference was close to significance [t(23)=2.02, p=0.055, d = 0.40, BF+0=2.32]. How-
ever, it is important to note that the pleasantness ratings for M- trials remembered at 24 hr were not
different from 0 at any session [Risperidone mean rating =  0.23, t(23)=-1.03, p=0.309, d = 0.20,
BF10 = 0.34; Placebo mean rating = 0.24, t(23)=1.01, p=0.319, d = 0.20, BF10 = 0.34; Levodopa
mean rating = 0.30, t(23)=1.20, p=0.240, d = 0.23, BF10 = 0.40], implying that participants did not
find this learning condition particularly rewarding even if the pharmacological intervention slightly
modified their subjective ratings.
Given that our learning task modulates activity within the reward network and is associated with
increased subjective reports of pleasure (Ripollés et al., 2014; Ripollés et al., 2016), we further
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tested whether individual differences in sensitivity to reward interacted with the drug intervention to
modulate memory benefits (Ferreri and Rodriguez-Fornells, 2017; de Vries et al., 2010; Apitz and
Bunzeck, 2013). Twenty-four out of the 26 participants completed the Physical Anhedonia Scale
(PAS; Chapman et al., 1976); mean score = 11.62 ± 5.47). The PAS is a well-validated scale that
evaluates difficulty in feeling physical and aesthetic pleasure in response to typical pleasurable stim-
uli (Padrão et al., 2013; Mas-Herrero et al., 2014). We correlated (using Spearman´s rho) partici-
pants’ individual scores with the drug effect for each learning condition (the drug effect was
calculated as the subtraction of the percentage of change from placebo of the levodopa intervention
minus the percentage of change from placebo of the risperidone intervention, see Materials and
methods). As a control and in order to take into account previous results (Chowdhury et al., 2012),
we also assessed the relationship of the learning scores with the weight-dependent measure of drug
dose (calculated in mg of levodopa/risperidone administered per kilogram, mean
value = 1.66 ± 0.23). As expected, no significant correlations were found between the M- learning
scores and the PAS [Learning Day 1 rs =  0.19, p=0.372; number of correctly rejected words during
Day 2, rs =  0.34, p=0.097; recognition rate, rs =  0.19, p=0.372]. In addition, no significant linear
correlation or inverted U-shape relationship (Chowdhury et al., 2012) was found for any learning
Figure 1. Effects of the pharmacological intervention (mean ± SEM) in (a) Learning and memory scores and (b) subjective ratings. Note that subjective
ratings were only measured during the learning phase of Day 1. Effects are calculated as % of change with respect to the placebo session. *p<0.05,
**p<0.01.
DOI: https://doi.org/10.7554/eLife.38113.002
The following figure supplement is available for figure 1:
Figure supplement 1. Mean plus standard error of the mean M+ scores for risperidone (black), placebo (white) and levodopa (grey) interventions
separately for (A) learning and memory measures, (B) learning and memory measures separated for high (H+; black line) and low (H-; grey line) hedonic
participants and (C) subjective ratings.
DOI: https://doi.org/10.7554/eLife.38113.003
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score (M+ or M-) and the weight dependent drug dosage (all ps > 0.13). However, for the drug
effect for M+ trials, the number of learned words during encoding (rs =  0.45, p=0.025), the total
number of remembered words during Day 2 (rs =  0.67, p<0.001) and, strikingly, the recognition
rate (rs =  0.49, p=0.017), showed a significant correlation with the PAS (all correlations were FDR-
corrected at a p<0.05 threshold, see Figure 2A). One participant was excluded from the correlations
with the learning scores on Day 2 after being identified as a bivariate outlier (note that if included,
the correlations become more significant: number of remembered words during Day 2, rs =  0.71,
p<0.001; recognition rate, rs =  0.55, p=0.005). Importantly, this participant obtained the highest
(more anhedonic) score on the PAS (score of 24, more than two standard deviations above the mean
score of 11.62 of the group). Additional correlational analyses with the results of each intervention
separately (risperidone, placebo, levodopa) instead of the drug effect only, further confirm a rela-
tionship between learning and memory scores and the PAS, with Spearman’s rhos for this relation-
ship being consistently lower than placebo for risperidone and higher than placebo for levodopa
(see the Supplemental Correlational Analyses section of Appendix 1 and Figure 2—figure supple-
ment 1). Although the correlation between the drug effect (calculated as the subtraction of the per-
centage of change from placebo of the levodopa intervention minus the percentage of change from
placebo of the risperidone intervention) for pleasantness ratings and the PAS was not significant for
Figure 2. Relation between the effect of the pharmacological intervention for the M+ condition and subjective sensitivity to reward for the learning
scores (i.e., online Learning on Day 1, Words Remembered on Day 2; Recognition Rate on Day 2) obtained by (A) correlating drug effect and PAS
scores (the lower the PAS values are, the higher the general hedonia); (B) computing the drug effect (mean ± SEM) according to high (Hedonic +) and
low (Hedonic -) hedonic subjects (median split using the PAS). *p<0.05, **p<0.001.
DOI: https://doi.org/10.7554/eLife.38113.004
The following figure supplements are available for figure 2:
Figure supplement 1. Correlations between the PAS and the different measures of M+ learning and memory during risperidone, placebo or levodopa
interventions.
DOI: https://doi.org/10.7554/eLife.38113.005
Figure supplement 2. Correlations between the PAS and the M+ subjective ratings during risperidone, placebo or levodopa interventions.
DOI: https://doi.org/10.7554/eLife.38113.006
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the main condition of interest (M+, rs =  0.274, p=0.196), raw pleasantness ratings during placebo
and levodopa interventions separately were indeed correlated with participants’ individual differen-
ces in sensitivity to reward (see the Supplemental Correlational Analyses section of Appendix 1 and
Figure 2—figure supplement 2 ).
Altogether, this pattern of results suggests that the dopaminergic pharmacological intervention
induced greater memory and accuracy benefits/deficits in those participants with high sensitivity to
reward. Note that the drug effect for the recognition rate, which showed no differences in memory
performance when pooling all participants together, becomes significant if we divide our partici-
pants into high and low sensitivity to reward (i.e. hedonic) groups [U = 35, p=0.033, h2 = 0.19,
BF+0=2.81; groups divided according to the median split of their PAS scores; due to the reduced N
of the groups we used a Mann-Whitney non-parametric statistical tests, see Materials and methods,
Figure 2B, Appendix 1 and Figure 1-Figure supplementary 1B]. This difference was also present
when comparing high/low groups for the number of words learned during encoding [U = 33,
p=0.024, h2 = 0.21, BF+0=4.34] and the total number of words remembered on Day 2 [U = 12.5,
p<0.001, h2 = 0.49, BF+0=78.74].
All in all, these results show that the dopaminergic pharmacological intervention did have an
effect in terms of both online learning and subjective pleasantness in our learning task, inducing
greater memory benefits in those participants more sensitive to reward.
Discussion
By using a double-blind, within-subject randomized pharmacological intervention during a learning
task—guided by an intrinsically regulated reward process—known to activate the SN/VTA-HP loop
(Ripollés et al., 2016), we showed that dopamine can modulate the entrance of new information
into long-term memory. In particular, the administration of a dopaminergic precursor (levodopa) and
a dopaminergic antagonist (risperidone), increased and decreased, respectively, both the learning
rate and the level of pleasantness experienced by the participants during encoding, as well as the
number of words remembered after a consolidation period (24 hr; see Figure 1B). Strikingly, the
memory effects induced by the dopaminergic pharmacological intervention were stronger in partici-
pants with a higher sensitivity to reward (i.e. more hedonic; see Figure 2).
In a previous study using the same task (Ripollés et al., 2016), we showed that successful learning
was in itself (i.e. in the absence of external feedback) associated with increased reward processing
and heightened activity within the SN/VTA and the VS. We suggested that this intrinsic reward-
related signal induced a higher release of dopamine in the HP, which ultimately resulted in enhanced
memory formation due to the well-known role of dopamine in mediating LTP processes. The mem-
ory effects reported here (after a 24 hr consolidation period) are also in agreement with the predic-
tion that the SN/VTA-HP loop should specially enhance delayed memory (Lisman and Grace, 2005;
Lisman et al., 2011; Adcock et al., 2006; Wittmann et al., 2005; Wolosin et al., 2012;
Murayama and Kitagami, 2014). In addition to the delayed memory effects reported, here we show
that dopamine had an additional role during online learning on Day 1: participants not only learned
more words (i.e. they performed better) under levodopa than under risperidone, but also found the
learning experience more rewarding when potentiating, rather than hindering, dopaminergic synap-
tic signaling. This result is in accord with previous work demonstrating that dopamine improves feed-
back-based learning in humans (de Vries et al., 2010) and also with research showing that internally
generated signals of self-performance—driven by mesolimbic areas and in absence of external feed-
back—can guide and improve perceptual learning in humans (Daniel and Pollmann,
2012; Daniel and Pollmann, 2014; Guggenmos et al., 2016) and song learning (i.e. motor perfor-
mance) in songbirds (Mandelblat-Cerf et al., 2014). Moreover, these results also converge with pro-
posals highlighting the role of internally triggered and regulated reward signals in sustaining intrinsic
motivation to perform activities that allow acquiring and storing new information (Gottlieb et al.,
2013; Berlyne, 1960). Importantly, the ability to glue information acquisition activities to internal
reward mechanisms might have been crucial to the evolutionary success of humans (e.g. increasing
environmental control, acquiring language; Barto, 2013; Ripollés et al., 2014).
An interesting interpretation of our results is therefore that the level of dopamine directly
affected the reward value or the salience (Knecht et al., 2004) of the learning outcome in our task
(i.e. learning was more enjoyable), prompting participants to be more motivated (Murty and
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Adcock, 2014) and to perform better. The VS, through its connections to the prefrontal cortex (PFC;
Lehéricy et al., 2004; Cummings, 1993; Alexander et al., 1986), is located in a perfect anatomical
position to add information about the relevance, salience and motivational value (Berridge and Krin-
gelbach, 2008) of the stimuli to be learned into the SN/VTA-HP loop. As both the VS and the PFC
are known to contain and receive dopaminergic receptors and projections (Haber and Knutson,
2010), dopamine might be able to alter this input, thus modulating the perceived reward underpin-
ning the learning processes. This, together with the significant correlation between the PAS and the
memory and learning scores (see Figure 2), is also in agreement with previous studies showing that
anhedonia is associated with both reduced activity and connectivity between regions within the mes-
olimbic reward pathway (especially between the VS and the SN/VTA; Keller et al., 2013). An alter-
native explanation, which cannot be fully ruled out, is that the benefit in performance was driven by
the suggested role of dopamine in working memory and attention (Surmeier, 2007; Brozoski et al.,
1979; Linssen et al., 2014; Drijgers et al., 2012; Mehta and Riedel, 2006). However, the fact that
no significant learning or memory benefits were induced in the control M- condition and, especially,
the relationship between the learning improvements during the encoding phase and the partici-
pants’ sensitivity to reward (for a similar effect, see Ferreri and Rodriguez-Fornells, 2017), suggest
that the learning enhancement was partially driven by reward-related and dopamine-dependent pro-
cesses (Diehl and Gershon, 1992; Nieoullon and Coquerel, 2003; de Vries et al., 2010).
The dopaminergic-dependent memory effects reported in this work are also in line with previous
studies using risperidone and levodopa, although note that there is a lack of data on the memory
effects of risperidone in healthy humans. The cognitive effects caused by the blockade of D2 recep-
tors have usually been studied in the treatment of schizophrenia (Rabella et al., 2016;
Désaméricq et al., 2014), with antipsychotic drugs (including risperidone) sometimes improving
cognitive function (Keefe et al., 1999), but also leading to impairments in several cognitive domains
(Sakurai et al., 2013), including executive functions and memory (Uchida et al., 2009; Hori et al.,
2006). On the other hand, levodopa intake has been related to improvements in feedback-based
grammar learning (de Vries et al., 2010), semantic activation and priming (Angwin et al., 2004 and
Angwin et al., 2009; Copland et al., 2009) and, most importantly, memory and learning
(Shellshear et al., 2015; Knecht et al., 2004; Chowdhury et al., 2012). In this vein, the studies in
which levodopa intake was related to long-term memory benefits, used associative learning tasks
and suggested that the memory enhancements occurred possibly due to the increase of the levels
of dopamine in the HP (Shellshear et al., 2015; Knecht et al., 2004; Chowdhury et al., 2012).
However, our findings draw a more complex and perhaps more informative picture: the lack of a
clear and significant memory enhancement for the control M- condition and the fact that more
hedonic participants benefitted the most from the dopaminergic intervention only in the learning
condition related to reward (M+), suggest that when using a reward-based learning task (Apitz and
Bunzeck, 2013; Patil et al., 2017; Oyarzún et al., 2016; Kizilirmak et al., 2016; de Vries et al.,
2010), the level of memory enhancement depends on dopamine synaptic signaling, but also on indi-
vidual differences in sensitivity to reward (Ferreri and Rodriguez-Fornells, 2017; Mas-
Herrero et al., 2014; Camara et al., 2010; Marco-Pallarés et al., 2009; Padrão et al., 2013). This
discovery can be crucial for dopamine-related pharmacological interventions in, for example, clinical
populations with language deficits (Berthier et al., 2011). Indeed, studies with levodopa in aphasia
recovery, have resulted in both positive (Seniów et al., 2009) and negative (Breitenstein et al.,
2015; Leemann et al., 2011) effects. In this type of therapy, in which patients try to learn of re-learn
words that are no longer accessible (Brady et al., 2012), the intensity of the language training is
usually related with recovery (Bhogal et al., 2003) and it has been suggested that high-training
intensity may cause a ceiling effect that prevents levodopa from providing additional memory bene-
fits (Breitenstein et al., 2015; Leemann et al., 2011). A reward-based learning task such as the one
used here, along with a better understanding of the interaction between the dopaminergic precursor
and the patient’s hedonic state could aid to achieve a more personalized and efficient rehabilitation
success, without the need for high intensive training.
In conclusion, here we show that a dopaminergic pharmacological intervention is able to modu-
late behavioral measures of pleasantness, task-performance and long-term memory according to
inter-individual differences in reward sensitivity. These findings further advance the idea that learn-
ing—even when achieved using a task guided by intrinsic reward—is a dopamine-dependent
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Around 150 individuals responded to advertisements and were contacted for a first phone pre-
screening. Of those, 45 confirmed their availability and, after giving informed consent, were admit-
ted at the hospital for further screening, medical examination and laboratory exams (blood and
urine analysis). The study was approved by the Ethics Committee of Hospital de la Santa Creu i Sant
Pau and the Spanish Medicines and Medical Devices Agency (EudraCT 2016-000801-35). The study
was carried out in accordance with the Declaration of Helsinki and the ICH Good Clinical Practice
Guidelines. All volunteers gave their written informed consent to participation prior to any
procedure.
Subjects were judged healthy at screening 3 weeks before the first dose based on medical his-
tory, physical examination, vital signs, electrocardiogram, laboratory assessments, negative urine
drug screens, and negative hepatitis B and C, and HIV serologies. The volunteers were excluded if
they had used any prescription or over-the-counter medications in the 14 days before screening, if
they had a medical history of alcohol and/or drug abuse, a consumption of more than 24 or 40
grams of alcohol per day for female and male, respectively, or if they smoked more than 10 ciga-
rettes/day. Women with a positive pregnancy test or not using efficient contraception methods and
subjects with musical training or those unable to understand the nature and consequences of the
trial or the testing procedures involved were also excluded. Additionally, volunteers were requested
to abstain from alcohol, tobacco and caffeinated drinks at least during the 24 hr prior to each exper-
imental period.
Twenty nine volunteers were randomized and completed the study (19 females, mean
age = 22.83 ± 4.39) in exchange of a monetary compensation according to the Spanish Legislation.
The original sample size was chosen to be 30 participants, but one participant dropped out early in
the study and only 29 finalized it. This sample size was selected based on several criteria, including
the recommendation that, in order to achieve 80% of power, at least 30 participants should be
included in an experiment in which the expected effect size is medium to large (Cohen, 1988). In
addition, we took into account the sample sizes of previous studies using levodopa to modulate
memory (range: between 10 and 30 participants; Apitz and Bunzeck, 2013; Copland et al., 2009,
de Vries et al., 2010 Knecht et al., 2004; Chowdhury et al., 2012; Shellshear et al., 2015) and
our previous behavioral studies using the same learning task (24 participants; Ripollés et al., 2016).
We also computed a sample size analysis using the G*Power program, which showed that a sample
size of 28 was required to ensure 80% of power to detect a significant effect (0.25) in a repeated-
measures ANOVA with three sessions at the 5% significance level. We excluded three participants
from the analyses after showing very poor memory performance on the word learning task during
the placebo session (on Day 2, they remembered less than four of the M+ words learned during the
encoding session). The final sample analyzed for this learning paradigm consisted of 26 participants
(17 women, mean age = 22.27 ± 3.69).
Study design and procedure
This double-blind, crossover, treatment sequence-randomized study was performed at the Neuro-
psychopharmacology Unit and Center for Drug Research (CIM) of the Santa Creu i Sant Pau Hospital
of Barcelona (Spain). Experimental testing took place over three sessions. For each session, partici-
pants arrived at the hospital under fasting conditions and were given a light breakfast. Subsequently,
they received in a double-blind masked fashion a capsule containing the treatment (see Appendix 2
for details about counter-balancing across drug and placebo sessions): a dopaminergic precursor
with an inhibitor of peripheral dopamine metabolism (levodopa, 100 mg + carbidopa, 25 mg), a
dopamine receptor antagonist (risperidone, 2 mg), or placebo (lactose). The dopaminergic system
has a physiological or intrinsic state whose effects are most likely reflected by the values of the
dependent variables measured during the placebo session. In this study, we intended to lower and
raise this baseline dopaminergic state by means of two independent pharmacological interventions
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involving low-to-moderate doses of levodopa and risperidone. Drug doses were carefully chosen to
be low enough to induce the desired modulation but not too large to allow collateral effects to
become a confounding factor. In particular, the levodopa dose was kept in line with previous studies
in healthy participants and within the dose range administered in clinical practice for the treatment
of Parkinson’s disease. While a higher dose could have been administered, increasing the likelihood
of the dependent variables showing statistically significant differences when compared with placebo,
this would have led to an unacceptable higher risk of adverse events (e.g. dangerous decreases in
blood pressure, intense nausea and vomiting, prominent general discomfort). In addition, increasing
the levodopa dose could also induce negative effects on cognition due to the inverted U-shaped
effects of dopamine (Chowdhury et al., 2012). Regarding risperidone, a higher dose could have
also confounded the experiment due to the well-known sedative effects risperidone can induce in
healthy volunteers when administered at higher doses. Thus, drug doses use were decided upon
these ethical concerns and the binding request on the part of our local Institute Review Board.
After 1 hr of completing several behavioral tasks not described in the current manuscript, the par-
ticipants completed our word learning task which lasted 45 min approximately. Next, participants
spent their time in a resting room and were allowed to leave the hospital after 6 hr from the treat-
ment administration. For each session, each participant came back 24 hr after for a behavioral retest-
ing (without any pharmacological intervention), which lasted about 15 min. At least 1 week passed
between one session and the other.
Experimental word learning task
The task was virtually identical to that of our previous work (Ripollés et al., 2014; Ripollés et al.,
2016; Ripollés et al., 2017). Stimuli were presented using the Psychophysics Toolbox 3.09 (Brai-
nard, 1997) and Matlab version R2012b. Stimuli consisted of 168 pairs of eight word-long Spanish
sentences ending in a new-word, built with an increasing degree of contextual constraint (Mestres-
MisseMissé et al., 2007; Mestres-Missé et al., 2014). Mean cloze probability (the proportion of
people who complete a particular sentence fragment with a particular word) was 29.16 ± 18.95% for
the first sentence (low constraint), and 81.67 ± 11.80% for the second (high constraint). The new-
words respected the phonotactic rules of Spanish, were built by changing one or two letters of an
existing word (mean number of letters = 6.02 ± 0.99) and always stood for a noun (mean frequency
43.26 ± 78.94 per million).
For each of the three different sessions, only half of the pairs of sentences disambiguated multi-
ple meanings, thus enabling the extraction of a correct meaning for the new-word (M+ condition; e.
g., 1. ’Every Sunday the grandmother went to the jedin’2. ’The man was buried in the jedin’; jedin
means graveyard and is congruent with both the first and second sentences). For the other pairs,
second sentences were scrambled so that they no longer matched their original first sentence. In
this case, the new-word was not associated with a congruent meaning across the sentences (M- con-
dition; e.g., 1. ’Every night the astronomer watched the heutil’. Moon is one possible meaning of
heutil. 2. ’In the morning break co-workers drink heutil.’ Coffee is now one of the possible meanings
of heutil, which is not congruent with the first sentence). These constituted the M- condition in which
congruent meaning extraction was not possible. To ensure that both stimulus types were equally
comparable, participants were told that it was just as crucial to learn the words of the M+ condition
as it was to correctly reject the new-words from the M- condition.
Given that the pharmacological intervention included three sessions, we created three versions of
our task that only differed in the stimuli being presented. Thus, the 168 pairs of sentences were
divided into six lists of 28 pairs (as aforementioned, two conditions, M+ and M-, were presented in
each of the three sessions). The six lists were created so that there were no differences (one-way
ANOVA) in the cloze probability of the sentences [first sentences: F(5,162)=0.688, p=0.633,
h2 = 0.021, BF10 = 0.044; second sentences: F(5,162)=0.419, p=0.835, h2 = 0.013, BF10 = 0.03], the
frequency of the meanings of the real words to be learned [F(5,162)=1.324, p=0.256, h2 = 0.039,
BF10 = 0.13] or the total number of letters of the new-words [F(5,162)=1.10, p=0.360, h2 = 0.033,
BF10 = 0.09]. The six lists of sentences were randomly assigned in pairs to the three different ses-
sions. Presentation of the lists was counterbalanced across the experiments so that half of the times
one list was used for the M+ condition and the other half for the M-. For each participant, new-
words were randomly assigned to each pair of sentences.
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During each session, four pairs of M+ and four pairs of M- sentences were presented per learning
block (7 blocks in total). Therefore, a total of 28 new-words from the M+ and 28 from the M- condi-
tions were presented during each of the three sessions. In order to achieve an ecologically valid par-
adigm, presentation of the first and second sentences with the same new-word at the end were
separated in time. The four first sentences of each of the M+ and M- conditions (a total of eight
new-words) were presented in a pseudo-randomized order (e.g., M + 1A, M-1A, M-1B, M-1C,
M + 1B, M + 1C, M + 1D, M-1D). Then, the second ‘pair’ sentences+ and M- conditions were pre-
sented (i.e. second presentation of the identical eight new-words), again in a pseudo-randomized
order (e.g. M-2C, M-2B, M + 2B, M + 2D, M-2D, M + 2C, M + 2A, M-2A). The temporal order of the
different new-words during first sentence presentation was not related in any systematic way to the
order of presentation of the same new-words for their second sentence. Participants were instructed
to produce a verbal answer 8 s after the new-word of a second sentence appeared. If participants
thought that the new-word had a congruent meaning, they had to provide its meaning in Spanish
(e.g. graveyard). If the new-word had no consistent meaning, they had to say the word incongruent.
If they did not know whether the new-word had a consistent meaning or not, they had to remain
silent. Vocal answers were recorded and later corrected (for the M+ condition, incorrect answers
included misses, providing the wrong meaning or saying incongruent; for the M- condition, incorrect
answers included misses or providing any meaning at all). After giving a verbal answer, participants
first provided a confidence rating that allowed for the assessment of the subjective evaluation of
their performance. Specifically, subjects were requested to enter, using the keyboard, a value
between  4 and 4 (9 point scale with 0 as the neutral value). Then, participants had to rate their
emotions with respect to arousal and pleasantness using the 9-point (as with confidence ratings,
from  4 to 4) visual Self-Assessment Manikin scale (SAM). For valence/pleasantness, the SAM ranges
from a sad, frowning figure (i.e. very negative) to a happy, smiling figure (i.e. very positive). For
arousal, the SAM ranges from a relaxed figure (i.e. very calm) to an excited figure (i.e. very aroused).
All participants completed a training block to familiarize them with the task.
Each trial started with a fixation cross lasting 1000 ms, continued with the seven first Spanish
words of the sentence presented for 2 s, and was followed by a 1-s duration dark screen. The new-
word was presented for 1000 ms and was followed by 7 s of a small fixation point presented in the
middle of the screen. For first sentences, a new trial was presented after 3 s of dark screen. For sec-
ond sentences, after this period, a screen with the word Answer appeared and subjects had 3 s to
produce a verbal answer. Then, the confidence and SAM scales for pleasantness and arousal were
sequentially presented (the experiment did not continue until participants provided a rating). Finally,
a new second sentence trial started after 3 s of dark screen. All words were placed in the middle of
a black screen with a font size of 22 and in white color.
To avoid biasing our results, participants were not told at any point prior to the start of the exper-
iment that the goal of the study was to assess whether the learning of a new-word and its meaning
was intrinsically rewarding. Instead, they were told that the objective of the study was to assess how
reading load affects mood and that, in order to ensure that there was a real reading load, they had
to learn the words of the M+ condition and to detect the incongruence of the new-words from the
M-. Finally, participants were told that they had to give pleasantness and arousal ratings when the
second sentences appeared because that moment signaled that reading load had already occurred
(i.e. half of the encoding block had already elapsed). After the experiment, participants were first
questioned about the objective of the study. None of them answered that it was to assess whether
word-learning was rewarding.
Approximately 24 hr after the learning lesson ended, participants returned to the lab to complete
a recognition test (note that no drugs were administered to subjects on Day 2). In this test, partici-
pants were presented, in a pseudo-randomized order, with all the 28 M+ and 28 M- new-words
used during the encoding session. This test was devised in order to assess which of the learned
words during encoding were still remembered and which of them had been forgotten after a 24 hr
retention period. Participants were aware that they would complete this test before completing the
encoding session. It was made explicit that they would assess both M+ and M- new-words during
the test phase. In the test, participants were presented with a new-word at the centre of the screen
with two possible meanings below: one on the left and one on the right. If the new-word tested did
not have a congruent meaning associated between the first and the second sentence, and thus cor-
rect meaning extraction was not possible (M- condition), participants had to press a button located
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in their left hand. In this case, the two possible meanings presented served as foils: one was the
meaning evoked by the second sentence of the M- new-word being tested; the other word shown
was the meaning evoked by another second sentence presented in the same run as the new-word
being tested. Instead, if the new-word tested had a consistent meaning through the first and second
sentence, and thus correct meaning extraction was possible (M+ condition), participants had to
select the correct meaning among the two presented. In this case, one of the two possible meanings
was correct and the other, which served as a foil, was the meaning of another new-word presented
in the same run. In addition, participants could also press a fourth button if they did not know the
answer. Thus, chance level was at 25% (no consistent meaning, consistent meaning on the left, con-
sistent meaning on the right, not remembered).
Statistical analyses for confidence, pleasantness and arousal subjective
scales and learning scores for encoding and retrieval
We first assessed whether the results of the placebo session replicated our previous behavioral data
(Experiment 3 in Ripollés et al., 2016). Besides the three subjective ratings, for these first compari-
sons, we used two additional scores: the percentage of words learned on Day 1 (total number of
words learned divided by the total number of words presented) and the recognition rate (total num-
ber of words learned during encoding and remembered on Day 2 divided by the number of words
learned during Day 1). For the analyses regarding the subjective scales, we divided our M+ trials
into those in which subjects learned the new-word during the learning session and still remembered
it in the test after the recognition test (remembered condition) and those in which the new-word was
not correctly identified in the 24 hr test (forgotten condition). We used the same approach to divide
the M- trials into those in which a word was correctly marked as incongruent during encoding and
still correctly rejected after 24 hr and those in which the new-word was not correctly rejected in the
follow-up test. To replicate our previous results, we first used paired t-tests to compare whether rat-
ings for confidence, arousal and pleasantness were greater for remembered than for forgotten M
+ and M- new-words. We then submitted both the ratings and the learning scores to a mixed
repeated measures ANOVA with Condition (M+,M-) as a within-subjects variable and Group (Phar-
macological Group, Exp. 3 in Ripollés et al., 2016) as a between subjects variable.
Given that current behavioral results replicate our previous work (see results) and that in our pre-
vious study (Ripollés et al., 2016) remembered M+ words were the trials showing the highest fMRI
activity within the SN/VTA-HP loop, the largest physiological response and the highest subjective
pleasantness ratings, we focused all the analyses regarding the effect of the pharmacological inter-
vention in the trials in which a word was learned during encoding and still remembered during the
recognition test at 24 hr (M+ condition). For the control condition, we used those M- trials in which
a word was correctly rejected during both encoding and the follow-up test. As measures for memory
effects, we used the total number of words learned during encoding and remembered on the fol-
low-up test and the percentage remembered words in the recognition test compared to the number
of learned words during the learning phase (i.e. the recognition rate). Note that these two measures
are delayed memory scores, while the percentage of learned words during Day 1 is an online learn-
ing rather than a pure delayed memory measure (participants try to learn the meaning of each new
word from the two sentences presented and then provide a verbal answer when the second sen-
tence is presented).
To ensure that no online learning or memory effects were present across sessions independent of
the treatment (i.e. participants could learn more on the third session just because they completed
the task twice before), we performed a control analysis for the percentage of learned words during
Day 1, total number of words remembered on Day 2 and the recognition test. For each score, we
computed a repeated measures ANOVA with Session (First, Second, Third; regardless of the treat-
ment) as the main factor. There was not a significant effect of session order regardless of the treat-
ment for the main M+ learning condition [percentage of learned words during Day 1: F(2,50)=0.957,
p=0.391, h2 = 0.037, BF10 = 0.236; total number of words remembered on Day 2: F(2,50)=0.489,
p=0.616, h2 = 0.019, BF10 = 0.161; recognition rate on Day 2: F(2,50)=0.263, p=0.770, h2 = 0.010,
BF10 = 0.133] or M- control condition [percentage of correctly rejected words during Day 1: F(2,50)
=0.964, p=0.388, h2 = 0.037, BF10 = 0.234; total number of correctly rejected words on Day 2: F
(2,50)=1.250, p=0.295 h2 = 0.048, BF10 = 0.284; recognition rate on Day 2: F(2,50)=0.604, p=0.550,
h2 = 0.024, BF10 = 0.176].
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The purpose of this study was to elucidate whether modulation of the dopaminergic system influ-
enced the variables under study (i.e. memory, learning and reward), rather than to assess the capac-
ity of the drugs themselves to block or enhance the natural physiological responses influenced by
dopamine. Levodopa and risperidone were chosen to ‘displace’ the baseline physiological system in
opposite directions: risperidone to lower the effects of physiological dopamine release and levo-
dopa to enhance dopaminergic neurotransmission. Thus, as the objective was to bring the dopami-
nergic system away from its intrinsic state (i.e. the placebo session) and in opposite directions, our
analyses focused in directly comparing the risperidone and levodopa data against each other by
using the placebo session as a baseline (but see Appendix 1 for analyses taking into account the
three pharmacological sessions separately). For each learning score and subjective scale, we calcu-
lated the percentage of change from the placebo session [e.g. (levodopa score - placebo score)/(pla-
cebo score)]. Therefore, for each participant, learning score and subjective scale, we obtained the
percentage of change from placebo of the risperidone and levodopa interventions. We used paired
t-tests to calculate whether the difference between the changes induced by the risperidone and
levodopa interventions were significant.
For the correlations between the learning scores and the PAS, we used Spearman’s rho with a
p<0.05 FDR correction to account for the three different correlations calculated per condition. The
PAS is one of the most easy to administer and well-validated tests for measuring reward sensitivity
and anhedonia. In addition, it shows convergent results with more modern tests measuring trait
anhedonia, as the Mood and Anxiety Symptom Questionnaire Short Form (Keller et al., 2013) or
the Temporal Experience of Pleasure Scale (Favrod et al., 2009). Some other psychometric meas-
ures of reward sensitivity and anhedonia that are translated and validated into Spanish, such as the
Sensitivity to Punishment/Sensitivity to Reward Questionnaire (Torrubia et al., 2001) or the BIS/BAS
(Caseras et al., 2003) show poorer alpha coefficients—less than 0.78 and 0.73, respectively—than
the PAS (0.92; Fonseca-Pedrero et al., 2009). Indeed, we have previously used the PAS in previous
studies exploring individual differences in anhedonia trait (Padrão et al., 2013; Mas-Herrero et al.,
2014; Martı́nez-Molina et al., 2016; Mas-Herrero et al., 2018). Here, the PAS was used as a proxy
to reflect the degree of pleasure taken by individuals when engaging in rewarding behavior (Der-
Avakian and Markou, 2012). Note that two participants were excluded from this analysis as they
did not complete the PAS. We also correlated the learning scores with a weight-dependent measure
of drug dose, calculated in mg of levodopa/risperidone per kilogram. Finally, we used the median
PAS value to split our final sample of 24 participants into high and low hedonic groups. For the
learning scores, we first calculated the drug effect as a subtraction of the percentage of change
from placebo induced by the levodopa intervention minus that induced by the risperidone interven-
tion. We then assessed were the total drug effect for the learning scores was different for high vs.
low hedonic groups by using a non-parametric test Mann-Whitney (to better account for the reduced
number of participants in each group).
For significant interactions of mixed between-within ANOVA models, partial eta squares (h2) is
provided as a measure of effect size. For significant differences in between group one-way ANOVAs,
eta squares (h2) is provided (calculated by dividing the between groups sum of squares by the total
sum of squares). For significant differences measured with t-tests, Cohen’s d is provided after apply-
ing Hedges’ correction (the average of the standard deviation of the variables being compared was
used as a standardizer; Cumming, 2012). For significant differences measured with the Mann-Whit-
ney test, eta squares (h2) is provided (calculated as Z2/N)
In addition, confirmatory Bayesian statistical analyses were computed with the software JASP
using default priors (JASP Team, 2018; Morey et al., 2015; Rouder and Morey, 2012;
Wagenmakers et al., 2018b; Wagenmakers et al., 2018a). We reported Bayes factors (BF10), which
reflect how likely data is to arise from one model, compared, in our case, to the null model (i.e. the
probability of the data given H1 relative to H0). For comparisons with a strong a priori, the alterna-
tive hypothesis was specified so that one group/condition was greater than the other (BF+0). We did
this, specifically, for the drug effects comparisons in which we expected levodopa and risperidone to
facilitate and disrupt learning/ratings, respectively; and for the group comparisons in which we
expected more hedonic participants to remember more words than less hedonic participants. For
mixed within-between models we used the Bayes Inclusion factor based on matched models, repre-
senting the evidence for all models containing a particular effect to equivalent models stripped of
that effect (BFInlcusion, also called Baws factor).
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persistence in old age. Journal of Neuroscience 32:14193–14204. DOI: https://doi.org/10.1523/JNEUROSCI.
1278-12.2012, PMID: 23055489
Cohen J. 1988. Statistical Power Analysis for the Behavioral Sciences Hillsdale. New Jersey: Lawrence Erlbaum
Associates.
Copland DA, McMahon KL, Silburn PA, de Zubicaray GI. 2009. Dopaminergic neuromodulation of semantic
processing: a 4-T FMRI study with levodopa. Cerebral Cortex 19:2651–2658. DOI: https://doi.org/10.1093/
cercor/bhp017, PMID: 19321651
Cummings JL. 1993. Frontal-subcortical circuits and human behavior. Archives of Neurology 50:873–880.
DOI: https://doi.org/10.1001/archneur.1993.00540080076020, PMID: 8352676
Daniel R, Pollmann S. 2012. Striatal activations signal prediction errors on confidence in the absence of external
feedback. NeuroImage 59:3457–3467. DOI: https://doi.org/10.1016/j.neuroimage.2011.11.058,
PMID: 22146752
Daniel R, Pollmann S. 2014. A universal role of the ventral striatum in reward-based learning: evidence from
human studies. Neurobiology of Learning and Memory 114:90–100. DOI: https://doi.org/10.1016/j.nlm.2014.
05.002, PMID: 24825620
de Vries MH, Ulte C, Zwitserlood P, Szymanski B, Knecht S. 2010. Increasing dopamine levels in the brain
improves feedback-based procedural learning in healthy participants: an artificial-grammar-learning
experiment. Neuropsychologia 48:3193–3197. DOI: https://doi.org/10.1016/j.neuropsychologia.2010.06.024,
PMID: 20600185
Der-Avakian A, Markou A. 2012. The neurobiology of anhedonia and other reward-related deficits. Trends in
Neurosciences 35:68–77. DOI: https://doi.org/10.1016/j.tins.2011.11.005, PMID: 22177980
Diehl DJ, Gershon S. 1992. The role of dopamine in mood disorders. Comprehensive Psychiatry 33:115–120.
DOI: https://doi.org/10.1016/0010-440X(92)90007-D, PMID: 1347497
Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. 2012. The role of the
dopaminergic system in mood, motivation and cognition in Parkinson’s disease: a double blind randomized
placebo-controlled experimental challenge with pramipexole and methylphenidate. Journal of the Neurological
Sciences 320:121–126. DOI: https://doi.org/10.1016/j.jns.2012.07.015, PMID: 22824349
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Levodopa: faster and better word learning in normal humans. Annals of Neurology 56:20–26. DOI: https://doi.
org/10.1002/ana.20125, PMID: 15236398
Knutson B, Gibbs SE. 2007. Linking nucleus accumbens dopamine and blood oxygenation. Psychopharmacology
191:813–822. DOI: https://doi.org/10.1007/s00213-006-0686-7, PMID: 17279377
Leemann B, Laganaro M, Chetelat-Mabillard D, Schnider A. 2011. Crossover trial of subacute computerized
aphasia therapy for Anomia with the addition of either levodopa or placebo. Neurorehabilitation and Neural
Repair 25:43–47. DOI: https://doi.org/10.1177/1545968310376938, PMID: 20834044
Lehéricy S, Ducros M, Van de Moortele PF, Francois C, Thivard L, Poupon C, Swindale N, Ugurbil K, Kim DS.
2004. Diffusion tensor fiber tracking shows distinct corticostriatal circuits in humans. Annals of Neurology 55:
522–529. DOI: https://doi.org/10.1002/ana.20030, PMID: 15048891
Linssen AM, Sambeth A, Vuurman EF, Riedel WJ. 2014. Cognitive effects of methylphenidate in healthy
volunteers: a review of single dose studies. The International Journal of Neuropsychopharmacology 17:961–
977. DOI: https://doi.org/10.1017/S1461145713001594, PMID: 24423151
Lisman J, Grace AA, Duzel E. 2011. A neoHebbian framework for episodic memory; role of dopamine-dependent
late LTP. Trends in Neurosciences 34:536–547. DOI: https://doi.org/10.1016/j.tins.2011.07.006
Ripollés et al. eLife 2018;7:e38113. DOI: https://doi.org/10.7554/eLife.38113 17 of 23
Research advance Neuroscience
Lisman JE, Grace AA. 2005. The hippocampal-VTA loop: controlling the entry of information into long-term
memory. Neuron 46:703–713. DOI: https://doi.org/10.1016/j.neuron.2005.05.002, PMID: 15924857
Mandelblat-Cerf Y, Las L, Denisenko N, Fee MS. 2014. A role for descending auditory cortical projections in
songbird vocal learning. eLife 3:e02152. DOI: https://doi.org/10.7554/eLife.02152
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Noesselt T. 2014. The role of reward in word learning and its implications for language acquisition. Current
Biology 24:2606–2611. DOI: https://doi.org/10.1016/j.cub.2014.09.044, PMID: 25447993
Ripollés et al. eLife 2018;7:e38113. DOI: https://doi.org/10.7554/eLife.38113 18 of 23
Research advance Neuroscience
Rossato JI, Bevilaqua LR, Izquierdo I, Medina JH, Cammarota M. 2009. Dopamine controls persistence of long-
term memory storage. Science 325:1017–1020. DOI: https://doi.org/10.1126/science.1172545, PMID: 196
96353
Rouder JN, Morey RD. 2012. Default bayes factors for model selection in regression. Multivariate Behavioral
Research 47:877–903. DOI: https://doi.org/10.1080/00273171.2012.734737, PMID: 26735007
Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M,
Uchida H. 2013. Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
Schizophrenia Bulletin 39:564–574. DOI: https://doi.org/10.1093/schbul/sbr189, PMID: 22290266
Salimpoor VN, Benovoy M, Larcher K, Dagher A, Zatorre RJ. 2011. Anatomically distinct dopamine release
during anticipation and experience of peak emotion to music. Nature Neuroscience 14:257–262. DOI: https://
doi.org/10.1038/nn.2726, PMID: 21217764
Schott BH, Minuzzi L, Krebs RM, Elmenhorst D, Lang M, Winz OH, Seidenbecher CI, Coenen HH, Heinze HJ,
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Torrubia R, Ávila C, Moltó J, Caseras X. 2001. The sensitivity to punishment and sensitivity to reward
questionnaire (SPSRQ) as a measure of gray’s anxiety and impulsivity dimensions. Personality and Individual
Differences 31:837–862. DOI: https://doi.org/10.1016/S0191-8869(00)00183-5
Uchida H, Rajji TK, Mulsant BH, Kapur S, Pollock BG, Graff-Guerrero A, Menon M, Mamo DC. 2009. D2 receptor
blockade by risperidone correlates with attention deficits in late-life schizophrenia. Journal of Clinical
Psychopharmacology 29:571–575. DOI: https://doi.org/10.1097/JCP.0b013e3181bf4ea3, PMID: 19910723
Wagenmakers EJ, Love J, Marsman M, Jamil T, Ly A, Verhagen J, Selker R, Gronau QF, Dropmann D, Boutin B,
Meerhoff F, Knight P, Raj A, van Kesteren EJ, van Doorn J, Šmı́ra M, Epskamp S, Etz A, Matzke D, de Jong T,
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While the purpose of this work was to elucidate whether modulation of the dopaminergic
system influenced the variables under study (i.e., intrinsically regulated learning), rather than to
assess the capacity of the drugs themselves to significantly block or enhance the natural
physiological responses influenced by dopamine, here we provide separated analyses for the
three different sessions (risperidone, placebo, levodopa) and the main condition of interest (M
+). Specifically, we used a repeated measures ANOVA with Intervention as a within subject
factor (Risperidone, Placebo and Levodopa) and paired post-hoc t-tests to re-analyze the data
for the learning and memory scores and the subjective ratings. For the learning measures,
taking into account the relationship between the PAS and the percentage of learned and
remembered words (see Figure 2 in the main text), we also calculated a 3  2 mixed repeated
measures ANOVAs with Intervention (Risperidone, Placebo and Levodopa) as the within and
Group (H+, H-) as the between group factor.
For the main M + learning condition, we found a main effect of Intervention for the
percentage of words learned on Day 1 [F(2,50)=5.041, p=0.01, partial h2 = 0.168,
BF10 = 4.524] and the total number of remembered words on Day 2 [F(2,50)=4.793, p=0.012,
partial h2 = 0.161, BF10 = 3.667; see Figure 1—figure supplement 1A]. Post-hoc paired
t-tests with Holm-Bonferroni correction showed, as expected, a significant difference between
the levodopa and the risperidone interventions for both online learning on Day 1 [t(25)=2.95,
p_corr = 0.02, d = 0.580, BF10 = 6.636] and the total number of words remembered on Day 2
[t(25)=2.44, p_corr = 0.044, d = 0.479, BF10 = 2.452]. Comparisons of levodopa against
placebo were not significant after the correction for multiple comparisons was applied [online
Learning on Day 1: t(25)=1.629, p_corr = 0.214, d = 0.319, BF10 = 0.663; Total Number of
Remembered Words on Day 2: t(25)=-0.240, p_corr = 0.812, d = 0.047, BF10 = 0.213]. The
risperidone vs. placebo comparison reached significance for the total number of remembered
words on Day 2 [t(25)= 2.90, p_corr = 0.023, d = 0.569, BF10 = 5.943], while was still not
significant for the percentage of learned words on Day 1 [t(25)= 1.63, p_corr = 0.214,
d = 0.328, BF10 = 0.704]. As expected, the recognition rate on Day 2 yielded no significant
main effect of Intervention [F(2,50)=1.661, p=0.20, partial h2 = 0.062, BF10 = 0.395].
When dividing the participants into two groups according to their PAS scores (H+, H-), a
significant Group x Intervention interaction was found for the total number of remembered
words on Day 2 [F(2,50)=7.825, p<0.001, partial h2 = 0.262, BFInclusion = 25.747], while for the
percentage of words learned on Day 1 [F(2,50)=2.786, p=0.073, partial h2 = 0.112,
BFInclusion = 1.204] and the recognition rate on Day 2 [F(2,50)=2.615, p=0.084, partial
h2 = 0.106, BFInclusion = 1.047] the interaction was marginally significant (see Figure 1—figure
supplement 1B).
Regarding the subjective ratings, as expected, there was a significant main effect of
Intervention for Pleasantness [F(2,50)=5.25, p=0.009, partial h2 = 0.174, BF10 = 5.15] and
Confidence [F(2,50)=3.70, p=0.032, partial h2 = 0.129, BF10 = 1.76], but not for Arousal [F
(2,50)=0.319, p=0.728, partial h2 = 0.013, BF10 = 0.141; see Figure 1—figure supplement
1C]. Post-hoc paired t-tests with Holm-Bonferroni correction showed that Pleasantness ratings
were higher under levodopa than under risperidone [t(25)=2.85, p_corr = 0.026, d = 0.560,
BF10 = 5.378], with no significant differences between the levodopa [t(25)=1.584,
p_corr = 0.137, d = 0.311, BF10 = 0.623] or risperidone interventions [t(25)= 1.903,
p_corr = 0.137, d = 0.373, BF10 = 0.985] against the placebo one. For Confidence ratings no
significant differences were found between any pair of interventions after applying the
correction for multiple comparisons [risperidone vs. placebo: t(25)=-2.275 p_corr = 0.095,
d = 0.446, BF10 = 1.816; risperidone vs. levodopa: t(25)=2.231, p_corr = 0.095, d = 0.438,
BF10 = 1.683; levodopa vs. placebo: t(25)=0.521, p_corr = 0.607, d = 0.102, BF10 = 0.235].
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The significant main effects and interactions for both memory and reward measures further
demonstrated that: i) the pharmacological intervention attained its main objective, which was
to bring the dopaminergic system away from its intrinsic state (i.e., the placebo intervention)
and in opposite directions (see, for example the Pleasantness ratings in Figure 1—figure
supplement 1C); ii) that intrinsically regulated learning is a dopamine-dependent mechanism;
and iii) that subject-specific reward/hedonic sensitivity drastically alters learning success
(modulations for memory and learning scores only happened in highly hedonic individuals, see
Figure 1—figure supplement 1B).
Supplemental correlational analyses
Following the same rationale as with the supplemental behavioral analyses above and taking
into account the significant correlations found between the drug effect (calculated as the
subtraction of the percentage of change from placebo of the levodopa intervention minus the
percentage of change from placebo of the risperidone intervention) and the PAS (see
Figure 2 in the main text), here we also calculated correlations (using Spearman´s rho)
between the PAS and all measures of learning, memory and the subjective ratings at each
intervention separately (a total of 18 correlations; we used a p<0.05 FDR corrected threshold
to control for the multiple correlations calculated).
Significant correlations (FDR corrected for multiple comparisons) between the PAS and the
percentage of learned words during Day 1, the total number of remembered words and the
recognition rate on Day 2 were found for the levodopa intervention (see Figure 2—figure
supplement 1). Regarding the subjective ratings, pleasantness was significantly correlated to
the PAS during the placebo and levodopa interventions (see Figure 2—figure supplement 2).
Confidence ratings were only significantly correlated to the PAS for the levodopa intervention,
while, as expected, no significant associations were found for arousal scores.
In addition, r scores were consistently lower than placebo for risperidone and higher than
placebo for levodopa. This implies that the relationship between the PAS and the different
measures of memory and learning and the pleasantness ratings was also modulated by the
drug intervention. These results further suggest that: i) the pharmacological intervention was
able to ‘displace’ the baseline physiological system in opposite directions, making the learning
experience more (levodopa) and less (risperidone) rewarding; ii) that this led to higher and
lower learning and retention rates; and iii) more hedonic participants were able to better
capitalize in the increase of the ‘rewarding experience’ (see, for example, the high correlation
between the PAS and the retention rate on Day 2 in the levodopa intervention in to
Figure 2—figure supplement 2).
Individual variability of the drug effect
As can be seen in Figure 2A, there were some participants who performed worse in terms of
learning and memory on levodopa than risperidone for the main learning condition M+ (i.e.,
showed a negative drug effect, calculated as the subtraction of the percentage of change
from placebo of the levodopa session minus the percentage of change from placebo of the
risperidone session). In particular, the number of participants who performed worse in the
levodopa than in the risperidone session was 6 for the percentage of learned words on Day 1,
6 for the total number of words remembered on Day 2, 9 for the recognition rate on Day 2
and 9 for the pleasantness ratings. However, there was not a single participant who showed a
negative drug effect in all three learning/memory scores and the pleasantness ratings at the
same time. In contrast, participants showed positive values in all memory and learning scores
and in the pleasantness ratings. In this vein, the drug effect for pleasantness did not
significantly correlate with any of the drug effects for learning and memory scores (learning on
Day 1: r =  0.04, p=0.829; total number of remembered words on Day 2: r = 0.108, p=0.608;
recognition rate on Day 2: r = 0.153, p=0.463).
If we assess the overlap for the learning and memory scores on their own, there was only
one participant showing a negative drug effect (levodopa minus risperidone) in the
percentage of learned words on Day 1, the total number of words remembered on Day 2 and
the recognition rate on Day 2 at the same time. In contrast, 12 showed positive values on the
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three measures. Indeed, while the drug effect for the percentage of learned words on Day 1
correlated with the drug effect for the total number of words remembered on Day 2
(r = 0.569, p<0.003), the relationship was not significant for the recognition rate on Day 2
(r =  0.084,p=0.689). Finally, 4 participants performed poorer in the levodopa than the
risperidone session for both the total number of words remembered on Day 2 and the
recognition rate on Day 2, while 15 participants showed positive values in both measures.
Indeed, the drug effects for these two memory measures are significantly correlated
(r = 0.638, p<0.001).





Treatment administration was randomized and balanced as shown in Appendix 2—table 1.
Treatment-letter assignment was performed randomly by a member of the Biometrics
department of Sant Pau Hospital, who kept the record unavailable to the investigators until
finalization of the experimental sessions.
Appendix 2—table 1. Counterbalancing across treatments, with six different sequences of
letters randomly assigned to N = 30. A corresponded to risperidone, B to placebo and C to
levodopa.
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